Abstract
We performed this meta-analysis to update the clinical evidences on the relation between clopidogrel non-responsiveness and clinical outcomes in patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention. An electronic literature search through MEDLINE, EMBASE, Web of Science, and the Cochrane Library and bibliographies of retrieved articles up to January, 2009 was conducted. Studies were included if they had a cohort prospective design, if they analysed clopidogrel responsiveness in CAD patients in relation to death and/or occurrence of adverse coronary events during followup, and if they reported an adequate statistical analysis. Fourteen studies, totalling 4,564 CAD patients followed for a time ranging from 14 days to one year, were included. The cumulative analysis reported that residual platelet reactivity despite clopidogrel treatment was significantly associated with an increased risk of death and/or thrombotic recurrences (odds ratio [OR] 5.67, 95% confidence interval [CI] 2.97 to 10.84; p
| Original language | English |
|---|---|
| Pages (from-to) | 841-848 |
| Number of pages | 8 |
| Journal | Thrombosis and Haemostasis |
| Volume | 103 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2010 |
Fingerprint
Keywords
- Antiplatelet therapy
- Clinical recurrences
- Clopidogrel
- Meta-analysis
ASJC Scopus subject areas
- Hematology
Cite this
Clopidogrel non-responsiveness and risk of cardiovascular morbidity : An updated meta-analysis. / Sofi, Francesco; Marcucci, Rossella; Gori, Anna Maria; Giusti, Betti; Abbate, Rosanna; Gensini, Gian Franco.
In: Thrombosis and Haemostasis, Vol. 103, No. 4, 04.2010, p. 841-848.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clopidogrel non-responsiveness and risk of cardiovascular morbidity
T2 - An updated meta-analysis
AU - Sofi, Francesco
AU - Marcucci, Rossella
AU - Gori, Anna Maria
AU - Giusti, Betti
AU - Abbate, Rosanna
AU - Gensini, Gian Franco
PY - 2010/4
Y1 - 2010/4
N2 - We performed this meta-analysis to update the clinical evidences on the relation between clopidogrel non-responsiveness and clinical outcomes in patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention. An electronic literature search through MEDLINE, EMBASE, Web of Science, and the Cochrane Library and bibliographies of retrieved articles up to January, 2009 was conducted. Studies were included if they had a cohort prospective design, if they analysed clopidogrel responsiveness in CAD patients in relation to death and/or occurrence of adverse coronary events during followup, and if they reported an adequate statistical analysis. Fourteen studies, totalling 4,564 CAD patients followed for a time ranging from 14 days to one year, were included. The cumulative analysis reported that residual platelet reactivity despite clopidogrel treatment was significantly associated with an increased risk of death and/or thrombotic recurrences (odds ratio [OR] 5.67, 95% confidence interval [CI] 2.97 to 10.84; p
AB - We performed this meta-analysis to update the clinical evidences on the relation between clopidogrel non-responsiveness and clinical outcomes in patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention. An electronic literature search through MEDLINE, EMBASE, Web of Science, and the Cochrane Library and bibliographies of retrieved articles up to January, 2009 was conducted. Studies were included if they had a cohort prospective design, if they analysed clopidogrel responsiveness in CAD patients in relation to death and/or occurrence of adverse coronary events during followup, and if they reported an adequate statistical analysis. Fourteen studies, totalling 4,564 CAD patients followed for a time ranging from 14 days to one year, were included. The cumulative analysis reported that residual platelet reactivity despite clopidogrel treatment was significantly associated with an increased risk of death and/or thrombotic recurrences (odds ratio [OR] 5.67, 95% confidence interval [CI] 2.97 to 10.84; p
KW - Antiplatelet therapy
KW - Clinical recurrences
KW - Clopidogrel
KW - Meta-analysis
UR - http://www.scopus.com/inward/record.url?scp=77952075376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952075376&partnerID=8YFLogxK
U2 - 10.1160/TH09-06-0418
DO - 10.1160/TH09-06-0418
M3 - Article
C2 - 20135063
AN - SCOPUS:77952075376
VL - 103
SP - 841
EP - 848
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
SN - 0340-6245
IS - 4
ER -